Bourne Partners Strategic Capital has been a founding investor in Covis Pharma since its inception in 2011.

Bourne Partners CEO, Banks Bourne, responded to the news of the transaction: “Covis Pharma has been an incredible growth story. The journey began in 2009 when two former GSK executives came to see our team about a plan to build a specialty pharma business. For over 18 months we worked with the team to establish the final business plan, select assets to acquire, and arrange all committed capital for the transaction. In 2011, we were thrilled to partner with Brett Ingersoll, Jim Lenehan, and the team at Cerberus, along with Mike Wells and his talented colleagues at Princeton Biopharma to co-found the go-forward platform. The management team, led by Michael Porter, has done a phenomenal job of rebuilding the business following the successful sale of 12 products in 2015 to Concordia Healthcare Group (now Advanz Pharma) for $1.2 billion. Since its inception, Covis acquired 23 products in 11 separate transactions (5 transactions originated by Bourne Partners). We wish the team and Apollo all the best in the next phase of Covis’ growth and would like to thank all the dedicated Covis employees and partners who contributed to this collaboration since 2009.”

To view the Cerberus release, click here.